Cost-effectiveness of healthcare interventions for rare cancers: evidence from a systematic literature review and meta-analysis
ConclusionCompared to NICE suggested thresholds and cost-effectiveness ratios of reimbursed interventions for common cancers, interventions for rare cancers seem to be value-for-money. More collaborative research is needed to realise their full potential for improving efficiency and equity in healthcare.
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | International Medicine & Public Health | Mesothelioma | Sarcomas | Study | Thyroid | Thyroid Cancer | UK Health